Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2003
06/12/2003WO2003047506A2 Peptide agonists of prostate-specific antigen, and uses therefor
06/12/2003WO2003047500A2 Vaccine and method for treatment of motor neurone diseases
06/12/2003WO2003047499A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
06/12/2003WO2003047421A2 Methods and reagents for diagnosis and treatment of diabetes
06/12/2003WO2002057465A3 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs
06/12/2003WO2002000844A3 Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
06/12/2003WO2001088126A8 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
06/12/2003WO2001073133A9 Compositions and methods for identifying and targeting cancer cells
06/12/2003US20030109689 Using polypeptides; induction immunology response
06/12/2003US20030109490 Composite stimulating iNOS enzyme which induce immuno-reactant nitric oxide synthesis and process for preparing the same
06/12/2003US20030109483 A purified Parapoxvirus ovis envelope protein termed "B2L" can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response
06/12/2003US20030109478 Nucleic acid formulations for gene delivery and methods of use
06/12/2003US20030109475 Introducing a gene capable of modulating the genotype and phenotype into two or more tissues following systemic administration. The gene can be introduced into a mammalian host by way of an expression vector either as naked DNA or
06/12/2003US20030109474 Gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor, of the signal transduction pathway is modified resulting in a modified AP-1 activity and
06/12/2003US20030109473 One dose vaccination with mycoplasma hyopneumoniae
06/12/2003US20030109472 Replicating adenovirus vectors
06/12/2003US20030109469 Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
06/12/2003US20030109454 Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109435 Methods of inhibiting amyloid toxicity
06/12/2003US20030109434 One or more kidney tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expression such
06/12/2003US20030109033 Feline calicivirus genes and vaccines in particular recombinant vaccines
06/12/2003US20030109026 Genetically modified tumor-targeted bacteria with reduced virulence
06/12/2003US20030109023 HIV-producing cell line and uses thereof
06/12/2003US20030109022 Asp2
06/12/2003US20030109018 Novel endometriosis-associated gene
06/12/2003US20030109003 Antitumor agent; transformation of expression vector; genetic engineering; process control hybrids
06/12/2003US20030108998 Aggrecan degrading metallo proteases
06/12/2003US20030108966 Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
06/12/2003US20030108965 Using polypeptide, detection of antibody; cancer of ovaries
06/12/2003US20030108950 Measuring concentration in body fluid of tumor antibodies
06/12/2003US20030108942 Methods for treatment of HIV and other infections using a T cell or viral activator and anti-retroviral combination therapy
06/12/2003US20030108927 Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
06/12/2003US20030108918 Inactivated vaccines for aids and other infectious diseases
06/12/2003US20030108916 Screening analysis using nucleic acids; antibodies, transgenic animals; antiproliferative agents; induction cell cycle delay
06/12/2003US20030108861 Comprises serum-free culture; protease-free
06/12/2003US20030108859 Enveloped virus vaccine and method for production
06/12/2003US20030108596 Lipophilic drug compositions
06/12/2003US20030108574 Carbohydrate-based whole cell cancer vaccines
06/12/2003US20030108572 Antigenic preparations and the isolation of such preparations
06/12/2003US20030108565 Sustained releas of protein using polymer and hydrophobic ion binding; inducing immunology response; autoimmune disease, anticancer agent
06/12/2003US20030108562 Administering gag protein; vaccines for human immunodeficiency virus
06/12/2003US20030108561 Core-glycosylated HCV envelope proteins
06/12/2003US20030108559 Induction immunology response; cardiovascular disorders, anticholesterol agents
06/12/2003US20030108557 Biosynthesis; contacting plant cell with genetic engineered nucleic acid virus; gene expression of fusion protein; splitting using cyanogen bromide
06/12/2003US20030108556 Using polymer containing dextran or ethylene glycol units
06/12/2003US20030108554 GIPs, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein
06/12/2003US20030108553 Detection and treatment of cancers of the liver
06/12/2003US20030108550 Anti-procalcitonin antibodies and the preparation and use thereof
06/12/2003US20030108545 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
06/12/2003US20030108544 Compositions and methods for the diagnosis and treatment of tumor
06/12/2003US20030108538 LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies
06/12/2003US20030108518 TRX1 antibody and uses therefor
06/12/2003US20030108517 Membrane-bound cytokine compositions and methods of modulating an immune response using same
06/12/2003US20030108516 Death domain containing receptor 4
06/12/2003US20030108515 Methods and compositions for inducing an immune response
06/12/2003US20030108514 Chemokines as adjuvants
06/12/2003US20030108483 Non-invasive localization of a light-emitting conjugate in a mammal
06/12/2003CA2811997A1 Antibodies against monocyte chemotactic proteins
06/12/2003CA2473883A1 Alloiococcus otitidis open reading frames (orfs) encoding polypeptide antigens, immunogenic compositions and uses thereof
06/12/2003CA2469671A1 A process for the preparation of a non-toxic anthrax vaccine
06/12/2003CA2469196A1 Discovery of therapeutic products
06/12/2003CA2469104A1 Minor histocompatibility antigen ha-1: target antigen for immunotherapy of tumors
06/12/2003CA2469092A1 Copolymer 1 vaccine and methods for treatment of amyotrophic lateral sclerosis (als)
06/12/2003CA2469078A1 Immunotherapeutic methods and systems
06/12/2003CA2468996A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
06/12/2003CA2468991A1 Methods and reagents for diagnosis and treatment of diabetes
06/12/2003CA2468935A1 Adjuvanted antigenic meningococcal compositions
06/12/2003CA2468851A1 Gips, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein
06/12/2003CA2468744A1 Hybrid antibodies
06/12/2003CA2468701A1 T-bet compositions and methods of use thereof
06/12/2003CA2468259A1 Antibody to latent membrane proteins and uses thereof
06/12/2003CA2467738A1 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
06/12/2003CA2467597A1 Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
06/12/2003CA2467486A1 Vaccine
06/12/2003CA2467073A1 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
06/12/2003CA2466413A1 Flavivirus ns1 subunit vaccine
06/11/2003EP1318407A1 Use of aldose-1-epimerase (mutarotase) for the diagnosis and therapy of infections and sepsis
06/11/2003EP1318401A2 Method for the early detection of the seroconversion of an anti hepatitis C virus antibody
06/11/2003EP1318195A1 A structure for presenting desired peptide sequences
06/11/2003EP1317927A1 Minor histocompatibility antigen HA-1: target antigen for immunotherapy of tumors
06/11/2003EP1317669A2 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
06/11/2003EP1317562A2 Test systems based on transmembrane receptors from helminths and the use thereof for identifying and characterizing compounds
06/11/2003EP1317559A2 Dna transfection system for the generation of infectious influenza virus
06/11/2003EP1317544A1 Novel diagnostic agents of chronic or persistent chlamydial diseases and uses thereof
06/11/2003EP1317540A2 Imidazoline receptor homologs
06/11/2003EP1317536A2 Tnf receptor-like molecules and uses thereof
06/11/2003EP1317489A1 A mixture of non-sulfated fucose-based oligosaccharides, a cosmetic or pharmaceutical composition comprising said mixture and its use in cosmetics or pharmacy
06/11/2003EP1317488A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine)
06/11/2003EP1317486A1 Interferon-alpha induced gene
06/11/2003EP1317485A2 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
06/11/2003EP1317484A2 VARIANTS OF i PHLEUM PRATENSE /i ALLERGENIC PROTEINS
06/11/2003EP1317481A2 Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
06/11/2003EP1317480A2 Rabbit hemorrhagic disease vaccine and antigens
06/11/2003EP1317479A2 Methods and compositions for diseases associated with amyloidosis
06/11/2003EP1317478A2 DISCRIMINATION BETWEEN GnRH-I AND GnRH-II
06/11/2003EP1317474A2 Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof
06/11/2003EP1317419A1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
06/11/2003EP1317285A1 Methods for treating demyelinating diseases
06/11/2003EP1317284A2 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
1 ... 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 ... 1823